Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Reeve, J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Reeve, J
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

British Medical Bulletin 48:458-468 (1992)
© 1992 The British Council

research-article

Future prospects for hormone replacement therapy

J Reeve

MRC Clinical Research Centre Harrow, UK

Abstract

To avoid the complication of osteoporosis, hormone replacement therapy (HRT) is now standard therapy in women with premature ovarian failure. The indications for HRT after the age of 50 are more controversial. There are strong indications from case-control studies that in N. America and Europe HRT protects against osteoporotic fracture, myocardial infarction and stroke; yet the evidence from case control studies is insufficiently precise to quantitate accurately the potential benefits that would accrue from its more widespread use. Clear guidelines also need to be established on the potential usefulness of selective prescribing of HRT using one or more screening procedures. The only effective way of achieving this and of quantitating the potential benefits of HRT with sufficient accuracy is by means of one or more randomized controlled trials. Future research will also address concerns such as the possible increase in the risk of breast cancer after 10 or more years of therapy. Critical to the more widespread acceptance of HRT may be the development of safe regimes which do not promote uterine bleeding as well as minimizing other unwanted side-effects.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 European Journal of Women's StudiesHome page
C. Roberts
Sex, Race and 'Unnatural' Difference: Tracking the Chiastic Logic of Menopause-Related Discourses
European Journal of Women's Studies, February 1, 2004; 11(1): 27 - 44.
[Abstract] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
P. J. Meunier, E. Confavreux, I. Tupinon, C. Hardouin, P. D. Delmas, and R. Balena
Prevention of Early Postmenopausal Bone Loss with Cyclical Etidronate Therapy (A Double-Blind, Placebo-Controlled Study and 1-Year Follow-Up)
J. Clin. Endocrinol. Metab., September 1, 1997; 82(9): 2784 - 2791.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.